Medivir

The first clinical data with MIV-711, demonstrating it to be safe and tolerable at doses which potently decrease bone resorption biomarkers indicating that MIV-711 exerts the intended pharmacological effect on bone resorption. MIV-711 is currently being evaluated in a phase Ib multiple ascending dose study for up to 4 weeks. The top line data will be available around mid-year, while the full further phase I data will be presented at a scientific conference later this year, said Charlotte Edenius, EVP Development, Medivir AB.

Portfolio

Medivir’s portfolio prioritize pharmaceuticals against infectious diseases caused by virus.
View portfolio

Financial information 2013

The Interim Report for January-June will be published on 22 August
The Interim Report for January-September will be published on 21 November

Simeprevir presented via a webcast

A fully owned subsidiary

Biophausia Logotyp

FDA grants priority review to Simeprevir

Hepatitis C - the silent epidemic

World Health Organization (WHO) estimates that about 170 million people are chronically infected by hepatitis C virus. Approximately 125,000 people in the Nordic countries is expected to carry the hepatitis C virus, and 5,000-6,000 cases are reported annually. This means that there is a daily average of 13-16 people in the Nordic countries receiving the news that they are carrying the hepatitis C virus.

Did you know ...?

About 75 per cent of those infected with hepatitis C in the world are unaware that they carry the virus.
People can be infected with hepatitis C virus for decades without knowing that the virus is in the body.
Approximately 70 per cent of all infected develop chronic liver disease, about 20 percent develop cirrhosis after 20-30 years of disease and 1-4 percent of them suffer every year from liver cancer.

Medivir AB
Blasieholmsgatan 2
111 48 Stockholm
Visit address: Hovslagargatan 5

Phone: 08-407 64 30
Fax: 08-407 64 39
E-mail: info@medivir.se
Org.nr. 556238-4361